High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Status:Active, not recruiting
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:November 2014
End Date:November 2019

Use our guide to learn which trials are right for you!

A Phase II Single Arm Study of High-Dose IL-2 and Ipilimumab in Patients With Unresectable Stage III and Stage IV Melanoma

This phase II trial studies how well high-dose aldesleukin and ipilimumab works in treating
patients with stage III-IV melanoma that cannot be removed by surgery. Biological therapies,
such as aldesleukin, may stimulate or suppress the immune system in different ways and stop
tumor cells from growing. Monoclonal antibodies, such as ipilimumab, interfere with the
ability of tumor cells to grow and spread. Giving high-dose aldesleukin together with
ipilimumab may work better in treating patients with melanoma.


I. The best overall response rate within the first 24 weeks of combination interleukin (IL)-2
(aldesleukin) and ipilimumab using the immune-related response criteria.


I. Best overall response (BOR). II. Progression-free survival (PFS). III. Disease control
rate (DCR). IV. Overall survival. V. To collect data on the safety and feasibility of
combined high-dose IL-2 and ipilimumab.

VI. To evaluate the cluster of differentiation (CD)4+ and CD8+ T cell response in the tumor
microenvironment and peripheral blood of patients treated on this study.


INDUCTION: Patients receive ipilimumab intravenously (IV) over 90 minutes on days 1, 22, 43,
and 64 and high-dose aldesleukin IV on days 22-26 and 43-47.

MAINTENANCE: Beginning on weeks 24, patients without disease progression or unacceptable
toxicity receive ipilimumab IV over 90 minutes once every 12 weeks for up to 24 weeks in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 36 months.

Inclusion Criteria:

- Willing and able to give written informed consent

- Histologic or cytologic diagnosis of cutaneous melanoma that is considered
unresectable (stage III) or metastatic (stage IV); ocular and mucosal melanoma is

- White blood cell (WBC) >= 2000/uL

- Absolute neutrophil count (ANC) >= 1000/uL

- Platelets >= 75 x 10^3/uL

- Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)

- Creatinine =< 2.0 x upper limit of normal (ULN)

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for
patients without liver metastasis, =< 5 times for patients with liver metastases

- Bilirubin =< 2.0 x ULN, (except patients with Gilbert's syndrome, who must have a
total bilirubin less than 3.0 mg/dL)

- No known active or chronic infection with human immunodeficiency virus (HIV),
hepatitis B, or hepatitis C; testing is not required unless clinically suspected

- Performance status (Eastern Cooperative Oncology Group [ECOG] 0-1)

- Patients must have a life expectancy of greater than three months at the start of the

- Patients must have a brain magnetic resonance imaging (MRI) that is free of active
metastases; metastases that have been treated with radiation or surgical resection,
are stable for at least 4 weeks and do not require steroids are eligible

- Patients may have received treatment of completely resected early stage melanoma,
comprising interferon, radiation treatment, or experimental vaccine therapy, and in
the metastatic setting patient can have had treatment such as chemotherapy,
immunotherapy (except prior treatment with ipilimumab and IL-2), and other
experimental agent which was completed 4 weeks prior to enrollment

- Normal cardiac stress test for patients over 50 years of age

- Forced expiratory volume in 1 second (FEV1) > 65% of prediction for those patients
with extensive pulmonary metastases or chronic pulmonary disease history

- Forced vital capacity (FVC) > 65% of prediction for those patients with extensive
pulmonary metastases or chronic pulmonary disease history

- Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for up to 26 weeks after the
last dose of investigational product, in such a manner that the risk of pregnancy is
minimized; in general, the decision for appropriate methods to prevent pregnancy
should be determined by discussions between the investigator and the study subject;
WOCBP include any female who has experienced menarche and who has not undergone
successful surgical sterilization (hysterectomy, bilateral tubal ligation, or
bilateral oophorectomy) or is not post-menopausal; post-menopause is defined as:

- Amenorrhea >= 12 consecutive months without another cause, or

- For women with irregular menstrual periods and taking hormone replacement therapy
(HRT), a documented serum follicle stimulating hormone (FSH) level >= 35 mIU/mL

- Women who are using oral contraceptives, other hormonal contraceptives (vaginal
products, skin patches, or implanted or injectable products), or mechanical
products such as an intrauterine device or barrier methods (diaphragm, condoms,
spermicides) to prevent pregnancy, or are practicing abstinence or where their
partner is sterile (eg, vasectomy) should be considered to be of childbearing

- WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25
IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 72 hours
before the start of ipilimumab

- Men of fathering potential must be using an adequate method of contraception to
avoid conception throughout the study (and for up to 26 weeks after the last dose
of investigational product) in such a manner that the risk of pregnancy is

Exclusion Criteria:

- Any other malignancy form which the patient has been disease-free for less than 5
years, with the exception of adequately treated and cured basal or squamous cell skin
cancer, superficial bladder cancer or carcinoma in situ of the cervix

- Patients with primary ocular or mucosal melanoma are excluded

- Patients with a history of inflammatory bowel disease, including ulcerative colitis
and Crohn's disease, are excluded from this study, as are patients with a history of
symptomatic disease (eg, rheumatoid arthritis, systemic progressive sclerosis
[scleroderma], systemic lupus erythematosus, autoimmune vasculitis [eg, Wegener's
granulomatosis]); motor neuropathy considered of autoimmune origin (e.g.
Guillain-Barre syndrome and Myasthenia Gravis)

- Any underlying medical or psychiatric condition, which in the opinion of the
investigator will make the administration of ipilimumab hazardous or obscure the
interpretation of adverse events (AEs), such as a condition associated with frequent

- Patients with underlying heart conditions who are deemed ineligible for surgery by
cardiology consult; patients with reversible ischemic changes on cardiac stress test

- Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to
1 month before or after any dose of ipilimumab)

- A history of prior treatment with IL-2, ipilimumab or prior cytotoxic T-lymphocyte
antigen 4 (CTLA4) inhibitor or agonist

- Concomitant therapy with any of the following: interferon, or other non-study
immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other
investigation therapies; or chronic use of systemic corticosteroids

- Women of childbearing potential (WOCBP), who:

- Are unwilling or unable to use an acceptable method of contraception to avoid
pregnancy for their entire study period and for at least 8 weeks after cessation
of study drug, or

- Have a positive pregnancy test at baseline, or

- Are pregnant or breastfeeding

- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (eg, infectious) illness
We found this trial at
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Marc S. Ernstoff
Phone: 603-650-7609
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Lebanon, NH
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Principal Investigator: David F. McDermott
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Boston, MA
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Jeffrey A. Sosman
Phone: 800-811-8480
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Nashville, TN
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Brendan D. Curti
Phone: 503-215-6412
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Portland, OR
Click here to add this to my saved trials
2160 South 1st Avenue
Maywood, Illinois 60153
(888) 584-7888
Principal Investigator: Joseph I. Clark
Phone: 708-226-4357
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
Maywood, IL
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Howard L. Kaufman
Phone: 732-235-8675
New Brunswick, NJ
Click here to add this to my saved trials